Form 4: Regulus Therapeutics CEO Hagan Joseph P Sells Shares to Cover Tax Obligations

Regulus Therapeutics CEO Joseph P Hagan sold shares of common stock on January 13 and 14, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Summary

• Regulus Therapeutics Inc. CEO Joseph P Hagan sold shares of the company's common stock on January 13 and 14, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• On January 13, 2025, 115,290 shares were sold at a price of $1.2632 per share, leaving Hagan with 222,572 shares.
• On January 14, 2025, an additional 11,764 shares were sold at the same price of $1.2632 per share, resulting in a holding of 210,808 shares.
• These sales were conducted under a pre-existing 10b5-1 plan, indicating that the CEO had irrevocably elected to satisfy tax obligations through these sales.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the stock sales are related to tax obligations and executed under a pre-existing plan, not necessarily reflecting a change in the CEO's confidence in the company.

Positives

• The sales are part of a pre-existing 10b5-1 plan, suggesting they were planned and not based on current market conditions or company performance.

Industry Context

Sales by insiders to cover tax obligations on vesting equity are common and generally don't signal a change in company outlook.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholders due to the increased supply of shares in the market, but this is likely to be minimal given the reason for the sales.

Key Dates